drugset / Trial / NCT03592472
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
RandomizedCrossoverDouble-blindTreatment
Summary
This is a randomized, Phase 3, double-blind, placebo-controlled study of pazopanib plus abexinostat versus pazopanib plus placebo in patients with locally advanced unresectable or metastatic renal cell carcinoma (RCC).
Timeline
- Start
- 2018-07-17
- Primary completion
- 2026-12-30
- Completion
- 2028-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abexinostat | Small molecule | 80 mg | Oral |
| Background | Pazopanib | Small molecule | 800 mg | Oral |